These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 35095993)

  • 1. RNA N6-Methyladenosine Regulators Contribute to Tumor Immune Microenvironment and Have Clinical Prognostic Impact in Breast Cancer.
    Mu LX; Shao YC; Wei L; Chen FF; Zhang JW
    Front Genet; 2021; 12():650499. PubMed ID: 35095993
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
    Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
    BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
    Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
    Front Immunol; 2021; 12():637933. PubMed ID: 33746977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
    Meijing Z; Tianhang L; Biao Y
    Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
    [No Abstract]   [Full Text] [Related]  

  • 6. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
    Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
    Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
    Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
    Front Oncol; 2021; 11():710767. PubMed ID: 34458149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of ligamentum flavum hypertrophy based on m6A RNA methylation modification and the immune microenvironment.
    He Z; Zhu Z; Tang T; Guo P; Gao M; Li B; Nguyen TCT; Chen H; Liu X; Zhou Z; Liu S
    Am J Transl Res; 2022; 14(12):8800-8827. PubMed ID: 36628248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

  • 11. m6A RNA methylation regulators play an important role in the prognosis of patients with testicular germ cell tumor.
    Cong R; Ji C; Zhang J; Zhang Q; Zhou X; Yao L; Luan J; Meng X; Song N
    Transl Androl Urol; 2021 Feb; 10(2):662-679. PubMed ID: 33718069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hub ten gene-based risk score system using RNA m
    Yuan B; Liu W; Huo M; Zhang J; Yang Y; Gao T; Yin X; Yang T; Teng X; Huang W; Yu H
    Breast Cancer; 2022 Jul; 29(4):645-658. PubMed ID: 35174450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of lncRNAs involved in m6A regulation for patients with ovarian cancer.
    Zheng J; Guo J; Cao B; Zhou Y; Tong J
    Cancer Cell Int; 2021 Jul; 21(1):363. PubMed ID: 34238292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.
    Quan Y; Zhang X; Ping H
    Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular subtype identification and predictive power of N6-methyladenosine regulator in unexplained recurrent pregnancy loss.
    Huo J; Chen Q; Zhang Y; Li N; Fu Z; Ma N; Zheng N; Cui N; Li L
    Front Genet; 2022; 13():925652. PubMed ID: 36118846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of N6-methylandenosine regulators and m6A-related RNAs as prognosis factors in colorectal cancer.
    Li W; Gao Y; Jin X; Wang H; Lan T; Wei M; Yan W; Wang G; Li Z; Zhao Z; Jiang X
    Mol Ther Nucleic Acids; 2022 Mar; 27():598-610. PubMed ID: 35070494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and validation of prognostic prediction established on N6-methyladenosine related genes in cervical squamous cell carcinoma.
    Chen D; Guo W; Yu H; Yang J
    Transl Cancer Res; 2022 Sep; 11(9):3064-3079. PubMed ID: 36237271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N6-methyladenosine Regulator-Mediated Immune Genes Identify Breast Cancer Immune Subtypes and Predict Immunotherapy Efficacy.
    Zhang MM; Lin YL; Zeng WF; Li Y; Yang Y; Liu M; Ye YJ; Jiang KW; Wang S; Wang S
    Front Genet; 2021; 12():790888. PubMed ID: 34976022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
    Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
    Front Genet; 2022; 13():872186. PubMed ID: 35937991
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
    Shen X; Zhong J; He J; Han J; Chen N
    Front Immunol; 2022; 13():978092. PubMed ID: 36105819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.